Among rare variants with counts ≥5, the p.A240G variant nominally increased risk of AMD in our study.
By region, intake nominally increased in 18 of 21 regions, although these increases only achieved statistical significance in South Asia (+3.8 g/day (0.6 7.4); see eTable 6).
In 2007, researchers found that variants within ARHGEF11 nominally increased the risk of T2D, possibly as a result of increased insulin resistance [ 103].
Point estimates were nominally increased for both ulcerative colitis and Crohn's disease (1.83, 0.96 to 3.47 and 1.39, 0.67 to 2.88, respectively).
The risk for aMCI patients was nominally increased in carriers of APOE ε4 allele combined with rs4880-T allele in the dominant model (OR = 3.17; 95% CI = 1.80 5.84, p < 0.001).
The hazard ratio was nominally increased for ulcerative colitis (1.45, 0.92 to 2.27) but not for Crohn's disease (1.05, 0.65 to 1.69).
Intake nominally increased in 13 regions, although these increases only achieved statistical significance in Southern Sub-Saharan Africa (+0.9%E (0.5 to 1.4)), Tropical Latin America (+0.6%E (0.3 to 0.9)), Central Latin America (+0.5%E (0.1 to 1.0)), and South Asia (0.4%E (0.2 to 0.6)).
Against this background, our finding of a nominally increased event risk with no statistical significance after multivariable adjustment appears reasonable, but does not add clarity to the ongoing dispute.
To get a rough idea of the effect of including these additional surfaces, we nominally increased all interior surface areas by a factor of 3 from the model baseline conditions.
In addition, larger genes and genes with a greater density of SNPs typed have an increased probability of harboring nominally significant SNPs just by chance.
